| NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS
- News), a cell
therapy company dedicated to the commercialization of stem cell products
for a variety of indications, today announced that it has evidence that
its PLX cells are immunosuppressive and immune privileged. These
characteristics could lead to breakthroughs in the treatment of
hematopoietic cancers and immune diseases. PLX cells are mesenchymal
stem cells (MSCs) obtained from the placenta and expanded by using
Pluristem's proprietary 3D PluriX(TM) technology. Immunosuppression is
defined as the quality of a product to attenuate or suppress the effects
of the immune system. Induced immunosuppression is generally practiced
to prevent the body from rejecting an organ or bone marrow transplant or
for the treatment of auto-immune diseases. Pluristem believes their
immunosuppressive PLX cells could have significant positive implications
in the development of products for a variety of therapeutic needs:
regenerative medicine, physiological diseases and immune diseases.
Additionally, this immune modulating property could prove important in
treating or preventing immune reactions associated with transplantation.
Ora Burger PhD. V.P. of R&D at Pluristem stated: "Our PLX cells
showed immune suppression characteristics during in vitro testing using
Mixed Lymphocyte Reaction assay (MLR). The immunosuppressive quality is
an important attribute for our first product, PLX-BMT, in the treatment of
hematological malignancies. Additionally, it has promising indications
for other applications involving the immune system."
William R. Prather RPh, MD, Sr. V.P. Corporate Development notes: "We
now have evidence that our PLX cells are immunosuppressive as well as
immune privileged. We believe these important characteristics underscore
our belief that placenta-derived MSCs expanded three dimensionally in
our PluriX(TM) bioreactor to become PLX cells are truly unique and may
prove valuable in the treatment of a variety of degenerative, malignant
and immune conditions."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven Company that is
developing and commercializing stem cell expansion technology products
for the potential treatment of a variety of disorders. The Company is
discovering and developing cell-based therapeutics that utilizes adult
stem cells expanded in a three-dimensional proprietary bioreactor termed
the PluriX(TM) that mimics different naturally occurring physiological
environments. Pluristem expects its first product, PLX-BMT, will provide
an efficient and superior alternative to the standard procedure of bone
marrow transplantation. PLX-BMT is intended to target a critical global
shortfall of matched tissue for bone marrow transplantation since bone
marrow transplantation is often the only cure for patients suffering
from leukemia, lymphoma, myeloma and many other hematological diseases.
The Company has made a strategic decision to work only with adult stem
cells since the practical use of embryonic stem cells is severely
restricted by various religious, ethical and legal considerations.
www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release, include: PLX
cells are immunosuppressive; These characteristics could lead to
breakthroughs in the treatment of hematopoietic cancers and immune
diseases; that immunosuppressive PLX cells could have significant
positive implications in the development of products for a variety of
therapeutic needs: regenerative medicine, physiological diseases and
immune diseases; that PLX cells possess immune suppression
characteristics that may be used for other applications; that it has
promising indications for other applications involving the immune
system; that our proprietary PluriX(TM) bioreactor that gives us the
unique capability to manufacture placenta-derived MSCs expanded three
dimensionally to produce PLX cells. Factors that could prevent our
forward looking statements from being achieved include: that we may be
unable to get regulatory approval for our products; we may be
unsuccessful in developing any products; our technology may not be
validated as we progress further and our methods may not be accepted by
the scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; results in the laboratory may not translate to equally good
results in real surgical settings; our patents may not be sufficient to
protect essential aspects of our technology; competitors may invent
better technology; our products may not work as well as hoped or worse,
our products may harm recipients; and we may not be able raise funds for
development or working capital when we require it. As well, our products
may never develop into useful products and even if they do, they may not
be approved for sale to the public. For further risk factors see the
Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
